Brief: Shanghai Henlius Biotech Says NMPA Approves Phase 1B/2 Trial For Hlx43 And Hlx07
30/09/2025 11:17
Sept 30 (Reuters) - Shanghai Henlius Biotech Inc 2696.HK: NMPA APPROVES PHASE 1B/2 TRIAL FOR HLX43 AND HLX07 Further company coverage: 2696.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shanghai Henlius Biotech
See all newsBrief: Shanghai Henlius Biotech Says Wenjie Zhang Resigns As Chairman
Brief: Shanghai Henlius Biotech Enters Collaboration And License Agreement With Amberstone Biosciences
Brief: Shanghai Henlius Biotech Says NDA For 120 Mg Biosimilar Denosumab HLX14 Accepted By NMPA
China's Henlius H1 revenue jumps on drug sales, license income
Brief: Shanghai Henlius Biotech Logs HY Profit RMB 430.4 Mln